Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide in early-stage poor-risk CLL
2009-011078-14Phase 2Terminated
- Sponsor
- The Christie
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by The Christie. Primary endpoint: Minimal residual disease-negative complete remission. Started Oct 2009; status: terminated.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2009-011078-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011078-14.